Related Experiment Videos

[Homocysteinemia and coronary artery disease: a case-control study in a Tunisian population]

M Souissi1, M Feki, S Mourali

  • 1Laboratoire de recherche Lab-SM-01, hôpital la Rabta, Tunis, Tunisie.

Archives Des Maladies Du Coeur Et Des Vaisseaux
|October 28, 2006
PubMed

Insights

Elevated homocysteine levels, a condition known as hyperhomocysteinemia, are more prevalent in Tunisian coronary heart disease patients. This study suggests hyperhomocysteinemia is an independent risk factor for coronary heart disease.

Area of Science:

  • Cardiovascular Medicine
  • Nutritional Biochemistry
  • Epidemiology

Context:

  • Coronary heart disease (CHD) is a leading cause of mortality worldwide.
  • Hyperhomocysteinemia, elevated homocysteine levels, is a potential risk factor for cardiovascular diseases.
  • Understanding the prevalence and association of hyperhomocysteinemia with CHD in specific populations is crucial for public health.

Purpose:

  • To determine the prevalence of hyperhomocysteinemia in Tunisian patients with angiographically proven coronary heart disease.
  • To investigate the relationship between hyperhomocysteinemia and coronary heart disease in this population.
  • To assess whether hyperhomocysteinemia is an independent risk factor for CHD, even after adjusting for other cardiovascular risk factors.

Summary:

  • This study analyzed plasma homocysteine, folate, and vitamin B12 levels in 70 Tunisian coronary heart disease patients and 140 healthy controls.
  • Hyperhomocysteinemia (homocysteine >17 micromol/L) was significantly more prevalent in patients (29%) compared to controls (10%).
  • A significant independent association was found between hyperhomocysteinemia and coronary heart disease (adjusted OR, 2.99; p=0.02), suggesting a role in atherothrombogenesis, though causality is not yet established.

Impact:

  • The findings highlight hyperhomocysteinemia as a significant, independent risk factor for coronary heart disease in the Tunisian population.
  • This suggests that screening for and managing hyperhomocysteinemia may be beneficial in patients with coronary heart disease.
  • Further research into homocysteine-lowering therapies is warranted to establish a causal relationship and guide clinical practice.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...